The drug didn’t make blood sugar or insulin levels better, so its benefits must come from somewhere else — likely directly on muscle energy production.

Taking tesamorelin for a year doesn't change blood sugar, insulin levels, or insulin resistance in obese people with low growth hormone.

Instead of giving growth hormone directly, this drug tricks the body into making its own in a natural rhythm, which might be safer for blood sugar.

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.

Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.

A hormone treatment called tesamorelin temporarily raises blood sugar by 7 points more than a placebo in people with HIV after two weeks of treatment, but this effect goes away after six months.